Tirzepatide's impact on breast cancer biology in patients evaluated in CLARA trial
Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial
Abstract
The CLARA trial is a phase II study investigating if tirzepatide, alone or with letrozole, reduces breast cancer cell growth.